Epizyme Announces Date of Second Quarter 2021 Financial Results

Rhea-AI Summary

Epizyme (Nasdaq: EPZM) will host a conference call on August 9, 2021, at 8:30 a.m. ET to discuss its second quarter 2021 financial results and provide a business update. The call can be accessed by dialing (877) 844-6886 for domestic participants or (970) 315-0315 for international attendees, using conference ID 3658407. A live webcast will be available on Epizyme's investor website and archived for 60 days. The company focuses on novel epigenetic therapies and has one FDA-approved product, TAZVERIK®, for specific cancer treatments.

Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call to discuss its second quarter 2021 financial results and provide a business update on Monday, August 9, 2021 at 8:30 a.m. ET.

To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 3658407. A live webcast will be available in the investor section of the company's website at www.epizyme.com, and will be archived for 60 days following the call.

About Epizyme, Inc.

Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). The company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them. For more information, visit www.epizyme.com.

TAZVERIK® is a registered trademark of Epizyme, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210803006035/en/

FAQ

When is Epizyme's second quarter 2021 financial results conference call?

Epizyme's conference call to discuss second quarter 2021 financial results is scheduled for August 9, 2021, at 8:30 a.m. ET.

How can I participate in Epizyme's conference call?

You can participate in Epizyme's conference call by dialing (877) 844-6886 for domestic calls or (970) 315-0315 for international calls, using conference ID 3658407.

What is TAZVERIK® and what conditions does it treat?

TAZVERIK® (tazemetostat) is an FDA-approved treatment for adults and pediatric patients with metastatic or locally advanced epithelioid sarcoma and certain types of follicular lymphoma.

Where can I find more information about Epizyme?

More information about Epizyme can be found on their official website at www.epizyme.com.

Will the Epizyme conference call be available for later listening?

Yes, the conference call will be archived for 60 days on Epizyme's investor website after the live event.